Research Analysts Set Expectations for LEXX FY2026 Earnings

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Equities researchers at Zacks Research lowered their FY2026 EPS estimates for Lexaria Bioscience in a research note issued on Friday, July 17th. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings of ($0.27) per share for the year, down from their prior estimate of ($0.26). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.27) per share.

Lexaria Bioscience (NASDAQ:LEXX) last issued its quarterly earnings data on Monday, July 13th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

Separately, Weiss Ratings raised Lexaria Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $1.50.

Lexaria Bioscience Stock Down 2.0%

Shares of NASDAQ:LEXX opened at $0.56 on Thursday. The firm has a market cap of $13.86 million, a P/E ratio of -1.64 and a beta of 0.34. Lexaria Bioscience has a 12-month low of $0.46 and a 12-month high of $1.55. The business has a fifty day simple moving average of $0.59 and a 200 day simple moving average of $0.71.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in LEXX. Geode Capital Management LLC boosted its stake in Lexaria Bioscience by 25.7% during the fourth quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock worth $136,000 after acquiring an additional 44,939 shares in the last quarter. Byrne Asset Management LLC increased its stake in Lexaria Bioscience by 236.8% in the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock valued at $65,000 after purchasing an additional 74,180 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Lexaria Bioscience during the third quarter valued at about $28,000. 13.06% of the stock is owned by institutional investors and hedge funds.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.